铜死亡在妇科恶性肿瘤中的研究进展

doi:10.12280/gjszjk.20230334

摘要/Abstract

摘要：

铜离子作为重要的辅酶，参与了广泛的代谢过程，包括有氧呼吸、肽酰胺化、铁转运、超氧化物歧化和细胞外基质的生物合成。铜稳态是维持细胞活性的重要机制。铜死亡是由铜离子积累引发的细胞死亡形式，其特点是铜稳态失衡，细胞内铜积累，选择性地扰乱三羧酸循环，使脂酰化线粒体酶聚集和铁硫蛋白丢失，引起线粒体蛋白质毒性应激，细胞膜裂解，最终导致细胞死亡。妇科恶性肿瘤是引起女性癌症死亡的重要原因。研究发现，铜死亡与妇科恶性肿瘤的发生、发展、预后及耐药密切相关。一些铜死亡调节剂可通过抑制血管生成、调节癌细胞的耐药性，抑制肿瘤转移和复发，因此铜死亡是治疗妇科恶性肿瘤有价值的研究方向。

关键词: 铜, 线粒体, 卵巢肿瘤, 宫颈肿瘤, 子宫内膜肿瘤, 铜死亡

Abstract:

Copper ion as an important coenzyme participates in a wide range of metabolic processes, including aerobic respiration, peptide amidation, iron transport, superoxide dismutase and extracellular matrix biosynthesis. Copper homeostasis is an important mechanism to maintain cell activity. Cuproptosis is a form of cell death caused by the accumulation of copper ions, which is characterized by the imbalance of copper homeostasis, the accumulation of copper in cells, the selective disturbance of tricarboxylic acid cycle, the aggregation of fatty acylated mitochondrial enzymes and the loss of iron-sulfur protein, the protein stress of mitochondria, the cell membrane cracking, and finally the cell death. Gynecological malignant tumors are important causes of cancer death in women. It is found that cuproptosis is closely related to the occurrence, development, prognosis and drug resistance of gynecological malignant tumors. Some cuproptosis regulators can inhibit tumor metastasis and recurrence by inhibiting angiogenesis and regulating drug resistance of cancer cells. Therefore, cuproptosis is a valuable research direction for the treatment of gynecological malignant tumors.

Key words: Copper, Mitochondria, Ovarian neoplasms, Uterine cervical neoplasms, Endometrial neoplasms, Cuproptosis

高亚婷, 王芳, 马建红, 马怡彤, 刘畅. 铜死亡在妇科恶性肿瘤中的研究进展[J]. 国际生殖健康/计划生育杂志, 2024, 43(1): 74-78.

GAO Ya-ting, WANG Fang, MA Jian-hong, MA Yi-tong, LIU Chang. Research Progress of Cuproptosis in Gynecologic Malignant Tumor[J]. Journal of International Reproductive Health/Family Planning, 2024, 43(1): 74-78.

图/表 1

参考文献 33

[1]	Wang Y, Zhang L, Zhou F. Cuproptosis: a new form of programmed cell death[J]. Cell Mol Immunol, 2022, 19(8):867-868. doi: 10.1038/s41423-022-00866-1. pmid: 35459854
[2]	朱洁洁, 王华. 铜诱导调节性细胞死亡的作用机制与抗肿瘤治疗的研究进展[J]. 江苏大学学报(医学版), 2022, 32(4):326-331,349. doi: 10.13312/j.issn.1671-7783.y220122.
[3]	Cobine PA, Brady DC. Cuproptosis: Cellular and molecular mechanisms underlying copper-induced cell death[J]. Mol Cell, 2022, 82(10):1786-1787. doi: 10.1016/j.molcel.2022.05.001. pmid: 35594843
[4]	艾文龙, 程楠, 韩咏竹. 细胞内铜稳态的分子调控机制研究进展[J]. 安徽医药, 2013, 17(5):724-726. doi: 10.3969/j.issn.1009-6469.2013.05.002.
[5]	Duan WJ, He RR. Cuproptosis: copper-induced regulated cell death[J]. Sci China Life Sci, 2022, 65(8):1680-1682. doi: 10.1007/s11427-022-2106-6.
[6]	Oliveri V. Selective Targeting of Cancer Cells by Copper Ionophores: An Overview[J]. Front Mol Biosci, 2022, 9:841814. doi: 10.3389/fmolb.2022.841814.
[7]	刘骏达, 钟薇薇, 鲁显福, 等. 铜死亡与铜代谢相关疾病研究进展[J]. 江苏大学学报(医学版), 2022, 32(4):318-325. doi: 10.13312/j.issn.1671-7783.y220108.
[8]	Anderson NM, Mucka P, Kern JG, et al. The emerging role and targetability of the TCA cycle in cancer metabolism[J]. Protein Cell, 2018, 9(2):216-237. doi: 10.1007/s13238-017-0451-1. pmid: 28748451
[9]	Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375(6586):1254-1261. doi: 10.1126/science.abf0529. pmid: 35298263
[10]	Li SR, Bu LL, Cai L. Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway[J]. Signal Transduct Target Ther, 2022, 7(1):158. doi: 10.1038/s41392-022-01014-x.
[11]	Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death[J]. Cell Res, 2022, 32(5):417-418. doi: 10.1038/s41422-022-00653-7. pmid: 35354936
[12]	Qin Y, Liu Y, Xiang X, et al. Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis[J]. Mol Cancer, 2023, 22(1):59. doi: 10.1186/s12943-023-01752-8. pmid: 36959665
[13]	Lukanović D, Herzog M, Kobal B, et al. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer[J]. Biomed Pharmacother, 2020, 129:110401. doi: 10.1016/j.biopha.2020.110401. pmid: 32570116
[14]	Liu H. Pan-cancer profiles of the cuproptosis gene set[J]. Am J Cancer Res, 2022, 12(8):4074-4081. pmid: 36119826
[15]	Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine[J]. CA Cancer J Clin, 2019, 69(4):280-304. doi: 10.3322/caac.21559.
[16]	Lin S, Yang H. Ovarian cancer risk according to circulating zinc and copper concentrations: A meta-analysis and Mendelian randomization study[J]. Clin Nutr, 2021, 40(4):2464-2468. doi: 10.1016/j.clnu.2020.10.011. pmid: 33129595
[17]	Sun X, Xu P, Zhang F, et al. The cuproptosis-related gene signature serves as a potential prognostic predictor for ovarian cancer using bioinformatics analysis[J]. Ann Transl Med, 2022, 10(18):1021. doi: 10.21037/atm-22-4546. pmid: 36267774
[18]	Guo J, Sun Y, Liu G. The mechanism of copper transporters in ovarian cancer cells and the prospect of cuproptosis[J]. J Inorg Biochem, 2023, 247:112324. doi: 10.1016/j.jinorgbio.2023.112324.
[19]	Cai Y, He Q, Liu W, et al. Comprehensive analysis of the potential cuproptosis-related biomarker LIAS that regulates prognosis and immunotherapy of pan-cancers[J]. Front Oncol, 2022, 12:952129. doi: 10.3389/fonc.2022.952129.
[20]	Zhang J, Lu M, Xu H, et al. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characterization in ovarian cancer[J]. Cancer Cell Int, 2022, 22(1):328. doi: 10.1186/s12935-022-02756-y. pmid: 36307842
[21]	Kordestani N, Rudbari HA, Fernandes AR, et al. Antiproliferative Activities of Diimine-Based Mixed Ligand Copper(Ⅱ) Complexes[J]. ACS Comb Sci, 2020, 22(2):89-99. doi: 10.1021/acscombsci.9b00202. pmid: 31913012
[22]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660.
[23]	Zhang M, Shi M, Zhao Y. Association between serum copper levels and cervical cancer risk: a meta-analysis[J]. Biosci Rep, 2018, 38(4):BSR20180161. doi: 10.1042/BSR20180161.
[24]	黄蓉. 双硫仑联合铜离子对人宫颈癌Hela细胞增殖的影响[D]. 衡阳: 南华大学, 2019.
[25]	Ishida S, McCormick F, Smith-McCune K, et al. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator[J]. Cancer Cell, 2010, 17(6):574-583. doi: 10.1016/j.ccr.2010.04.011. pmid: 20541702
[26]	Weng Y, Guan S, Wang L, et al. Defective Porous Carbon Polyhedra Decorated with Copper Nanoparticles for Enhanced NIR-Driven Photothermal Cancer Therapy[J]. Small, 2020, 16(1):e1905184. doi: 10.1002/smll.201905184.
[27]	Walker CA, Spirtos AN, Miller DS. Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma[J]. Expert Rev Anticancer Ther, 2023, 23(4):361-368. doi: 10.1080/14737140.2023.2194634.
[28]	Shan J, Geng R, Zhang Y, et al. Identification of cuproptosis-related subtypes, establishment of a prognostic model and tumor immune landscape in endometrial carcinoma[J]. Comput Biol Med, 2022, 149:105988. doi: 10.1016/j.compbiomed.2022.105988.
[29]	Zhang X, Ye Z, Xiao G, et al. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs[J]. Comput Biol Med, 2023, 159:106905. doi: 10.1016/j.compbiomed.2023.106905.
[30]	Qi S, Feng H, Li X. LncRNAs signatures associated with cuproptosis predict the prognosis of endometrial cancer[J]. Front Genet, 2023, 14:1120089. doi: 10.3389/fgene.2023.1120089.
[31]	Kim KK, Abelman S, Yano N, et al. Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1α in cancer cells[J]. Sci Rep, 2015, 5:14296. doi: 10.1038/srep14296. pmid: 26469226
[32]	高瑞, 唐杰, 朱炜, 等. 双硫仑靶向Wnt和AKT信号通路降低卵巢癌细胞的恶性程度及对顺铂的耐受性[J]. 深圳中西医结合杂志, 2022, 32(1):11-15. doi: 10.16458/j.cnki.1007-0893.2022.01.004.
[33]	Gan Y, Liu T, Feng W, et al. Drug repositioning of disulfiram induces endometrioid epithelial ovarian cancer cell death via the both apoptosis and cuproptosis pathways[J]. Oncol Res, 2023, 31(3):333-343. doi: 10.32604/or.2023.028694. pmid: 37305383